Mekinist ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanomul - agenți antineoplazici - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 și 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-cancer pulmonar cu celule mici (nsclc)trametinib în combinație cu dabrafenib este indicat pentru tratamentul pacienților adulți cu avansate non-cancer pulmonar cu celule mici, cu o mutație braf v600.

Ibuprofen 200 mg capsule moi মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ibuprofen 200 mg capsule moi

apotex inc. - ibuprofenum - capsule moi - 200 mg

Ibuprofen 400 mg capsule moi মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ibuprofen 400 mg capsule moi

apotex inc. - ibuprofenum - capsule moi - 400 mg

Imatinib Actavis ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

imatinib actavis

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.

Gazyva 1000 mg concentrat pentru soluţie perfuzabilă মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

gazyva 1000 mg concentrat pentru soluţie perfuzabilă

f.hoffmann-la roche ltd - obinutuzumabum - concentrat pentru soluţie perfuzabilă - 1000 mg

Nimid Forte comprimate 100 mg + 2 mg মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

nimid forte comprimate 100 mg + 2 mg

kusum healthcare pvt.ltd - nimesulidum + tizanidinum - comprimate - 100 mg + 2 mg

Gripocitron Hot Lemon pulbere pentru solutie orala 500 mg + 50 mg + 20 mg + 10 mg/4 g মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

gripocitron hot lemon pulbere pentru solutie orala 500 mg + 50 mg + 20 mg + 10 mg/4 g

zdorovie srl, companie farmaceutica - paracetamolum + acid ascorbicum + pheniraminum + phenylephrinum - pulbere pentru solutie orala - 500 mg + 50 mg + 20 mg + 10 mg/4 g

Gripocitron Hot Orange pulbere pentru solutie orala 500 mg + 50 mg + 20 mg + 10 mg/4 g মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

gripocitron hot orange pulbere pentru solutie orala 500 mg + 50 mg + 20 mg + 10 mg/4 g

zdorovie srl, companie farmaceutica - paracetamolum + acid ascorbicum + pheniraminum + phenylephrinum - pulbere pentru solutie orala - 500 mg + 50 mg + 20 mg + 10 mg/4 g

THROMBOREDUCTIN 0,5 mg রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

thromboreductin 0,5 mg

aop orphan pharmaceuticals ag - austria - anagrelidum - caps. - 0,5mg - alte antineoplazice alte antineoplazice

Ketorolac 30 mg/ml soluţie injectabilă মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ketorolac 30 mg/ml soluţie injectabilă

upm din borisov sad - ketorolacum - soluţie injectabilă - 30 mg/ml